Diabetes (type 2) - glitazones (TA63) (replaced by CG66)
Glitazones in the treatment of type 2 diabetes (Review of TA9 and TA21)
This guidance has been replaced by CG66 Type 2 diabetes (partially updated by CG87)
This page was last updated: 20 December 2011
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.